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Abstract: A sequence of seven reactions (stereocontrolled 
allylation, Mitsunobu reaction, ring closing metathesis and 
amino/amido intramolecular nucleophilic addition) eff iciently 
convert the inexpensive starting 2-piperidine ethanol in a small 
library of enatiomerically pure nitrogen containing compounds  
characterized by three new  scaffolds that present a relevant 
diversity. The simple approach results challenging to continue the 
exploration of the chemical space. 
Introduction 
Now adays, small molecules are an eff icient tool in medicinal 
chemistry, as entities to probe biological pathw ays and as 
potential drug candidates. Among the methods useful for the 
generation of small molecules, diversity-oriented synthesis (DOS)  
is a really appealing one. Signif icant achievements w ere recently 
obtained in this f ield, and DOS confirmed its importance as a tool 
for the discovery of novel, biologically interesting small 
molecules.[1-3] In contrast to other approaches, such as the 
targeted-oriented synthesis (TOS) or combinatorial chemistry , 
DOS aims to obtain a w ide distribution of compounds in the 
chemical space, investigating in this w ay its unexplored or poorly  
populated portions, that can be promising sources for drug 
discovery.[4, 5] 
In the f ield of DOS, different efforts w ere made in our laboratory  
in the last years, exploiting the 2-piperidine ethanol as versatile 
precursor. This reagent, w hich is really cheap in its racemic form, 
contains tw o handles – the piperidine nitrogen and the hydroxyl 
group – w hich can be easily further functionalized, increasing in 
this w ay the structural complexity. This prompted us to exploit the 
2-piperidine ethanol in a diversity-oriented approach aimed at the 
obtainment of a small library of piperidine-containing derivatives. 
Considering our interest in natural products, w e took advantage 
of this approach to synthesize some alkaloids (aloperine, [ 6 ]  
different sedum alkaloids,[7] dumetorine, epidihydropinidine, 
coniine,[8] boehmeriasin A [9]) but also some synthetic derivatives, 
such as polyheterocyclic derivatives [10] and hybrid compounds  
(Figure 1).[11,12]  
Results and Discussion 
Encouraged by the demonstrated versatility of the 2-piperidine 
ethanol, w e devised to further expand the library of piperidine -
based derivatives according to the synthetic plan depicted in 
Scheme 1.  
Figure 1. Structures of the previously synthesized compounds 
 
The exploitation of the reactivity of the aminoaldehyde 2 and the 
reaction sequence based on stereocontrolled allylation, 
Mitsunobu reaction, ring closing metathesis (RCM) and 
intramolecular amine/amide addition, sounded challenging for a 
further investigation of the unexplored chemical space. 
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Scheme 1. Forw ard-synthetic approach. 
 
The homoallylic alcohol 3, resulting from the stereocontrolled 
allylation of 2, w ould be converted into the corresponding amine. 
Acylation, follow ed by a ring closing metathesis, should lead to a 
6-membered unsaturated lactam 6. This scaffold appears to be a 
versatile starting point to achieve further structural diversif ications. 
The cleavage of the Boc protecting group should lead to the free 
amine 7, w hich could eventually undergo an intramolecular aza-
Michael addition, to generate the tricyclic compound 8. Under  
Eschw eiler-Clarke conditions, the obtained iminium salt could be 
reduced by hydrogen transfer, leading to compound 10, or 
attacked by the lactam nitrogen, affording the octahydrodipyrido 
pyrimidone 9. 
Thus, starting from 2, the synthesis of four new  polyheterocyclic  
scaffolds should be possible. 
Considering that the main scaffold 6 is characterized by the 
presence of tw o stereocenters, w e envisaged a stereodivergent 
protocol, aimed at the obtainment of all the possible 
stereoisomers. We planned to introduce stereo-divergency taking 
advantage of a highly stereoselective allylation on the racemic  
aldehyde 2.[13,14] 
In detail, aldehyde 2, obtained from the 2-piperidine ethanol as 
reported previously,[10] underw ent a Brow n’s asymmetr ic  
allylboration, to access all the four stereoisomers of the 
homoallylic alcohol 3. To this extent, 2 w as treated w ith both (+)- 
and (-)- B-allyl di-isopinocamphey lboranes, generated reacting 
the proper di-isopinocampheylboron chloride (DIP-Cl) enantiomer  
w ith allylmagnesium bromide. The diastereomeric alcohols 3a 
and 3b w ere obtained reacting the aldehyde w ith (-)- B-allyl di-
isopinocampheylborane, and w ere separated through column 
chromatography (d.r. ≈ 1 : 1). 
Using (+)-B-allyl di-isopinocampheylborane in the same 
conditions, 3c and 3d w ere accessed as w ell (d.r. ≈ 1 : 1), 
(Scheme 2). 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Reagent and conditions. a) (-)-allylBIpc2 (from (-)-DIP-
Cl and allylmagnesium bromide), THF, -78°C to r.t., 4 h, 90% 
overall yield; b) (+)-allylBIpc2 (from (+)-DIP-Cl and 
allylmagnesium bromide), THF, -78°C to r.t., 4 h, 88% overall 
yield; c) TFA, CH2Cl2, 0°C to r.t., 18h, yield: 90%. 
 
The relative syn/anti configuration w as assigned on the basis of 
X-rays analysis, performed on one of the anti- isomer, after the 
cleavage of the Boc protecting group, leading to 11 (Scheme 2). 
The relative (S, R) configuration w as secured by single-crystal X-
ray diffraction. Full details are reported in the Supplementary  
Materials (see also Figure S1). The absolute configuration is 
determined by the configuration of the used DIP-Cl. To confirm 
the absolute configuration, a stereoselective allylation w ith (+)-
DIP-Cl w as performed on small scale on the enantiopure 
aldehyde 2-(R),[15,16] confirming the obtainment of 3c.  
The enantiopurity of our alcohols w as determined through chiral 
HPLC on reverse phase. Syn-isomers (3a and 3c), w ere obtained 
w ith a 92% ee w hile the anti-alcohols (3b and 3d), w ere accessed 
w ith 84% ee. For syn-compounds, the result w as also confirmed 
through 1H-NMR, registering the spectra in the presence of (R)-
(−)-1-(9-anthryl)-2,2,2-trif luoroethanol[17] as chiral solvating agent. 
(Figure S3, Supp.Info.). 
With compounds 3a-d in our hands, a Mitsunobu reaction in the 
presence of diphenylphosphoryl azide (DPPA) w as performed,[18]  
follow ed by a Staudinger reduction of the obtained azide.[19] In this 
w ay, the interconversion of compounds 3a-d into the 
corresponding amines (4a-d) w as achieved w ith inversion of 
configuration. The amines w ere treated w ith acryloyl chloride (5a-
d), affording the amides, w hich w ere converted into lactams (6a-
d) through a ring-closing metathesis (RCM). Scheme 3 reports 
the three steps procedure for the conversion of 3a into 6a.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Reagent and conditions: a) i. PPh3, DIAD, DPPA, THF, 
0°C to r.t., 4h; ii. PPh3, THF/H2O 10:1, 5h, 40°C, yield: 62% over 
tw o steps; b) TEA, acryloyl chloride, CH2Cl2, 0°C to r.t., 2h, yield: 
63%; c) Ru-catalyst, CH2Cl2, 50°C, 1.5-7 h, yield: 73%. (Reported 
on compounds a as example) 
 
To this extent, tw o different catalysts w ere used: a 2nd generation 
Hoveyda-Grubbs (HG-II) (yields 54-60%) and a Umicore M73 
SIMes (yields 73-80%).[20] The latter resulted to be our catalyst of 
choice, because it proved to be more eff icient for the obtainment 
of products 6a-d, as reported in Scheme 3. Chiral HPLC analysis  
of these fundamental building blocks confirmed the maintenance 
of the previously observed enantiomeric excesses. 
Compounds 6a-d w ere treated w ith TFA, to remove the Boc 
protecting group. We realized that w hile syn-compounds gave the 
expected deprotected amines 7b and 7d, the anti-substrates 
underw ent directly the intramolecular aza-Michael addition on the 
α,β-unsaturated lactam, leading to the formation of the tricyclic 
compounds 8a and 8c (Scheme 4).The configuration of the new ly 
formed stereocenter at position 12 is defined by the configuration 
of the present stereocenters (Scheme 4). 
 
 
Starting material Product 
  H-2 H-8  H-2 H-8 H-12 Yield 
S
y
n
 
6b(2R, 8R) β β 7b(2R,8R) β β - 66% 
6d(2S,8S) α α 7d(2S,8S) α α - 70% 
A
n
ti
 
6a(2S, 8R) α β 8a(2S,8S,12R) α α α >95% 
6c(2R, 8S) β α 8c(2R,8R,12S) β β β >95% 
Scheme 4. Outcome of compounds 6 Boc removal. 
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The different outcome of compounds 6 deprotection can be 
explained taking into consideration the 3D structures and 
energies of the transition states leading to the tricyclic compounds  
8 (Figure 2). We hypothesize a late transition state (TS), similar  
in energy to the f inal products, according to Hammond’s postulate. 
The reactant and TS structure have been optimized w ith semi -
empirical calculations using the PM6 model.[21] The Intrinsic  
Reaction Coordinate pathw ay connecting reactants to the TS has 
been also calculated for both the diastereomers. Syn-compounds  
show ed a higher activation energy w ith respect to the anti-ones. 
In particular, the activation energy associated to the anti-
compounds is 9.28 Kcal/mol, w hile the activation energy of the 
syn-compounds is 11.54 Kcal/mol. The calculated activation 
energy difference of 2.26 Kcal/mol is in qualitative agreement w ith 
experimental results. This could explain w hy syn-products 6b and 
6d can be effectively deprotected, leading to 7b and 7d, w hile 
anti-products tend to cyclize, producing 8a and 8c. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Hypothetic transition states leading to the formation of 
the Michael adducts. 
 
Finally, an Eschw eiler-Clarke reaction[22-24] w as performed on all 
the stereoisomers of the fundamental scaffold 6, affording in all of 
the cases the octahydrodipyrido pyrimidinones 9 (Scheme 5) and 
not the corresponding methyl amines 10 (Scheme 1). 
 
 
 
Starting material Product 
  H-2 H-8  H-2 H-8 Yield 
S
y
n
 
6b(2R, 8R) β β 9b(2R, 8R) α β 80% 
6d(2S,8S) α α 9d(2S, 8S) β α 77% 
A
n
ti
 
6a(2S, 8R) α β 9a(2S, 8R) β β 68% 
6c(2R, 8S) β α 9c(2R, 8S) α α 65% 
Scheme 5. Outcome of Eschw eiler-Clarke reaction. 
 
The formation of scaffold 9 w as explained by the intramolecular  
nucleophilic attack of the lactam nitrogen on the imminium salt, 
w hich resulted to be favored over the hydride transfer by the 
formate anion. 
To obtain scaffold 10, a reduction of the imminium salt w ith a 
stronger reducing agent, such as NMe3∙BH3 complex, was 
attempted. Unfortunately, this reaction resulted in a complex  
mixture of products, impossible to purify. 
In summary, 16 compounds, presenting three new  scaffolds, were 
obtained through this DOS approach. It is notew orthy that 
compounds 8 presents the isomeric scaffold of some lupin 
alkaloids, such as cytisine, sparteine and anagyramide,[25-28] w hile 
products 9 are characterized by a simplif ied structure of several 
Lycopodium alkaloids, like lycocernuine and cernuine.[29,30]] 
 
Conclusions 
 
The described results confirm 2-piperidine ethanol as a valuable 
and versatile building block for the obtainment of diversif ied library  
of new  polycyclic nitrogen containing compounds. The availability  
of a versatile synthon makes diversity-oriented synthesis a fruitful 
tool for the exploration of the chemical space.[31] Seven reaction 
steps based on stereocontrolled allylation, Mitsunobu reaction, 
ring closing metathesis and amino/amido intramolecular  
nucleophilic additions generated three new  scaffolds w ith a 
relevant diversity. Computational studies support the different 
experimental outcomes of tw o diastereomeric compounds in the 
intramolecular aza-nucleophilic addition.  
 
Experimental Section 
 
Chemistry 
 
General: Unless otherw ise stated, reagents and solvents w ere 
purchased from Sigma Aldrich, Fluorochem or TCI and used 
w ithout further purif ication. All reactions w ere carried out in oven-
dried glassw are and dry solvents, under nitrogen atmosphere and 
w ere monitored by thin layer chromatography (TLC) on silica gel 
(Merck precoated 60F254 plates), w ith detection by UV light (254 
nm) or by solutions of potassium permanganate stain or ninhydrin.  
Flash chromatography w as performed using silica gel (240-400 
mesh, Merck) as stationary phase. 
1H-NMR spectra w ere recorded on a Bruker Avance 
Spectrometer and are reported relative to residual CDCl3 or 
CD3OD. 
13C-NMR spectra w ere recorded on the same 
instruments (100 MHz) and are reported relative to residual CDCl 3  
or CD3OD. All 1D and 2D NMR spectra w ere collected using the 
standard pulse sequences available w ith Bruker Topspin 1.3. 
Chemical shifts (δ) for proton and carbon resonances are quoted 
in parts per million (ppm) relative to tetramethylsilane (TMS), used 
as an internal standard. Data for 1H-NMR are reported as follow s: 
chemical shift (δ/ppm) (multiplicity, coupling constant (Hz), 
integration). Multiplicities are reported as follow s: s = singlet, d = 
doublet, t = triplet, m = multiplet, bs = broad singlet. Data for 13C-
NMR are reported in terms of chemical shif t (δ/ppm). 
Mass spectra w ere registered exploiting the electrospray  
ionization (ESI) technique, on a Q-Tof micro mass spectrometer. 
Specif ic rotation values w ere measured on a P-1030 Jasco 
polarimeter, using 1 mL cells, w ith path length of 10 cm. Measures  
w ere collected at 20-25°C, using sodium D line w avelength λ=589 
nm. HPLC analysis w ere performed using a 15 cm X 4.6 mm 
Chiralcel® AD-RH RP column at 35°C. Detection occurred at two 
different w avelengths (254 nm and 204 nm). 
 
General procedure for the synthesis of (S)-tert-butyl 2-((S)-2-
hydroxypent-4-enyl)piperidine-1-carboxylate (3a), (R)-tert-
butyl 2-((S)-2-hydroxypent-4-enyl)piperidine-1-carboxylate 
(3b), (R)-tert-butyl 2-((R)-2-hydroxypent-4-enyl)piperidine-1-
carboxylate (3c), (S)-tert-butyl 2-((R)-2-hydroxypent-4-
enyl)piperidine-1-carboxylate, (3d).[11] 
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Allylmagnesium bromide (1 M solution in Et2O, 2.86 mL, 2.86 
mmol) w as added dropw ise to a solution of (–)-DIP-Cl (1.06 g, 
3.30mmol) in anhydrous THF (13.5 mL), previously cooled at –
78 °C. The reaction mixture w as w armed to 0 °C and stirred at 
this temperature for 1 h. The solution w as allow ed to stand until 
magnesium chloride precipitated. The supernatant solution was 
carefully transferred to another f lask and cooled at -78°C.Then, a 
solution of aldehyde 2 (0.500 g, 2.20 mmol) in anhydrous THF 
(6.5 mL) w as added dropw ise. The resulting solution w as stirred 
at -78°C for 1 h and then 16 h at room temperature. The reaction 
w as quenched w ith NaH2PO4 buffer solution at pH 7 (13.5 mL) , 
MeOH (13.5 mL) and 30 % H2O2 (6.7 mL). After stirring for 30 min, 
the mixture w as w ashed w ith saturated aqueous NaHCO3 and 
extracted w ith Et2O. The combined organic phases w ere dried 
over Na2SO4 and f iltered. The solvent w as evaporated under  
vacuum, and the residue w as purif ied by column chromatography  
on silica gel (hexane/EtOAc, 8:2) to give 3a and 3b as yellow  oils  
(90% overall yield). In order to obtain the other couple of 
diastereomers (3c and 3d), the reaction w as performed in the 
same w ay, using the (+)-DIP-Cl. 
 
(S)-tert-butyl 2-((S)-2-hydroxypent-4-enyl)piperidine-1-
carboxylate (3a). Yield: 44%. 1H NMR (400 MHz, CDCl3): δ = 
5.81–5.91 (m, 1H), 5.08 (d, J = 17.4 Hz, 1H), 5.05 (d, J =9.7 Hz, 
1H), 4.47 (bs, 1H), 3.95 (bs, 1H), 3.39 (bs, 1H), 2.66 (dt, J = 12.7, 
2.0 Hz, 1H), 2.27–2.33 (m, 1H), 2.16–2.23 (m, 1H), 2.01 (dt, J = 
12.5, 1.8 Hz, 1H), 1.73–1.76 (m, 1H), 1.42 (s, 9H), 1.35–1.59 (m, 
6H) ppm. 13C NMR (100 MHz, CDCl3): δ = 167.1, 135.5, 116.6, 
80.2, 67.1, 46.2, 41.1, 39.3, 36.9, 29.2, 28.6, 25.3, 19.4 ppm. 
[α]D
20 = –33 (c = 1, CHCl3). ESIMS m/z [M + H]
+ calcd. for 
C15H28NO3: 270.2069, found: 270.2072. HPLC analysis: Chiralcel 
AD-RH RP column, 1 mL/min, CH3CN:H2O = 35:65, 96 bar, λ: 204 
nm, tR: 21.342 min, ee%: 92%. 
 
(R)-tert-butyl 2-((R)-2-hydroxypent-4-enyl)piperidine-1-
carboxylate (3c). Yield: 42% [α]D
20 = +35 (c = 0.8, CHCl3). ESIMS 
m/z [M + H]+ calcd. for C15H28NO3: 270.2069, found: 270.2073. 
HPLC analysis: Chiralcel AD-RH RP column, 1 mL/min, 
CH3CN:H2O = 35:65, 96 bar, λ: 204 nm, tR: 11.05 min, ee%: 92%. 
 
(R)-tert-butyl 2-((R)-2-hydroxypent-4-enyl)piperidine-1-
carboxylate (3b). Yield: 46%. 1H NMR (400 MHz, CDCl3): δ= 
5.85–5.75 (m, 1H), 5.10 (d, J = 17.3 Hz, 1H), 5.08 (d, J = 9.8 Hz, 
1H), 4.32 (br. s, 1H), 3.88–3.93 (m, 1H), 3.88–3.93 (m, 1H), 3.65 
(tt, J = 7.5, 2.4 Hz,1H), 2.79 (dt, J = 12.8, 0.2 Hz,1 H), 2.27–2.32 
(m, 1H), 2.14–2.21 (m, 1H), 1.77–1.82 (m, 1H), 1.42 (s,9 H), 1.35–
1.59 (m, 6H) ppm. 13C NMR (100 MHz,CDCl3): δ= 155.29, 135.06, 
117.4, 79.6, 71.3, 48.0, 41.8, 38.8, 37.0, 28.9, 28.4, 25.5, 18.9 
ppm. [α]D
20 = +15 (c = 0.9, CHCl3). ESIMS m/z [M+ H]
+ calcd. for 
C15H28NO3: 270.2069, found: 270.2071. HPLC analysis: Chiralcel 
AD-RH RP column, 1 mL/min, CH3CN:H2O = 35:65, 96 bar, λ: 204 
nm, tR: 8.12 min, ee%: 84%. 
 
(S)-tert-butyl 2-((R)-2-hydroxypent-4-enyl)piperidine-1-
carboxylate, (3d). Yield: 46%. [α]D
20 = –14 (c = 13.3, CHCl3 ) . 
ESIMS m/z [M +H]+ calcd. for C15H28NO3: 270.2069, found: 
270.2068. HPLC analysis: Chiralcel AD-RH RP column, 1 mL/min, 
CH3CN:H2O = 35:65, 96 bar, λ: 204 nm, tR: 9.24 min, ee%: 84%. 
 
General procedure for the synthesis of (S)-tert-butyl 2-((R)-2-
aminopent-4-enyl)piperidine-1-carboxylate (4a), (R)-tert-
butyl 2-((R)-2-aminopent-4-enyl)piperidine-1-carboxylate (4b), 
(R)-tert-butyl 2-((S)-2-aminopent-4-enyl)piperidine-1-
carboxylate (4c), (S)-tert-butyl 2-((S)-2-aminopent-4-
enyl)piperidine-1-carboxylate (4d). 
PPh3 (0.277 g, 1.06 mmol) w as added to a solution of 3 (0.237 g, 
0.88 mmol) in anhydrous THF (7.5 mL) at room temperature. The 
reaction mixture w as cooled at 0°C and 
diisopropylazodicarboxylate (DIAD) (209 µL, 1.06 mmol) was 
carefully added dropw ise. After 10 minutes , 
diphenylphosphorylazide (DPPA) (228 µL, 1.06 mmol) w as slowly 
added as w ell. The reaction mixture w as w armed to room 
temperature and stirred for 4 h. The solvent w as evaporated 
under vacuum and the residue w as purif ied by column 
chromatography on silica gel (Hexane/EtOAc, 95:5), to give the 
azide as a light yellow  oil, w hich w as immediately used in the next 
step. The azide (0.194 g, 0.66 mmol), w as dissolved in THF (11.5 
mL) and treated w ith PPh3 (0.346 g, 1.32 mmol) and w ater (1.2 
mL). The reaction mixture w as w armed to 40°C and stirred at that 
temperature for 5 h. The reaction mixture w as cooled to room 
temperature and w ater (5 mL) w as added carefully. The layers 
w ere separated and the aqueous one w as extracted w ith Et2O. 
The collected organic phases w ere w ashed w ith brine (5 mL) , 
dried over Na2SO4, f iltered and concentrated under vacuum. The 
crude product w as purif ied by column chromatography on silica 
gel (CH2Cl2/MeOH, 9:1) to give 4 as a light yellow  oil. 
 
(S)-tert-butyl 2-((R)-2-aminopent-4-enyl)piperidine-1-
carboxylate (4a). Yield: 62% over tw o steps. 1H NMR (400 MHz , 
CDCl3) δ 5.87 – 5.73 (m, 1H), 5.20 – 5.10 (m, 2H), 4.37 (m, 1H), 
3.96-3.94 (m, 1H), 3.30 (bs, 2H), 2.86-2.80 (m, 2H), 2.48 – 2.37 
(dt, J = 13.5, 5.3 Hz, 1H), 2.15 (dt, J = 13.3, 6.4 Hz, 1H), 1.97 – 
1.86 (m, 1H), 1.67 – 1.49 (m, 6H), 1.45 (s, 9H), 1.41-1.35 (m, 1H)  
ppm. 13C NMR (100 MHz, CDCl3) δ 154.97, 134.67, 118.38, 79.50, 
48.76, 47.80, 40.86, 38.99, 36.20, 29.02, 28.49 (3 CH3), 25.56, 
19.07 ppm. [α]D
20 = -30 (c = 1.02, CHCl3). ESIMS m/z [M + Na]
+  
calcd. for C15H28N2O2Na: 291.2048, found: 291.2051. 
 
(R)-tert-butyl 2-((S)-2-aminopent-4-enyl)piperidine-1-
carboxylate (4c). Yield: 65% over tw o steps, [α]D
20 = +33 (c = 
0.98, CHCl3). ESIMS m/z [M + Na]
+ calcd. for C15H28N2O2 Na: 
291.2048, found: 291.2049. 
 
(R)-tert-butyl 2-((R)-2-aminopent-4-enyl)piperidine-1-
carboxylate (4b).Yield: 67% over tw o steps, 1H NMR (400 MHz , 
CDCl3) δ 5.79 (ddt, J = 17.3, 10.1, 7.1 Hz, 1H), 5.15 (m, 2H), 4.43 
(m, 1H), 4.09 (bs, 2H), 3.96 (m, 1H), 2.81 – 2.62 (m, 2H), 2.58 – 
2.39 (m, 1H), 2.38-2.23 (m, 1H), 2.17 – 1.98 (m, 1H), 1.72 (m, 1H), 
1.63 – 1.50 (m, 4H), 1.47 (s, 9H), 1.43 – 1.32 (m, 2H) ppm. 13C 
NMR (100 MHz, CDCl3) δ 135.16, 118.90, 80.78, 48.43, 46.96, 
40.66, 39.70, 35.73, 30.01, 29.11 (3CH3), 26.15, 19.73 ppm 
(detected signals). [α]D
20 = +14 (c = 0.72, CHCl3). ESIMS m/z [M 
+ Na]+ calcd. for C15H28N2O2Na: 291.2048, found: 291.2052. 
 
(S)-tert-butyl 2-((S)-2-aminopent-4-enyl)piperidine-1-
carboxylate (4d). Yield: 64% over tw o steps, [α]D
20 = -11 (c = 0.85, 
CHCl3). ESIMS m/z [M + Na]
+ calcd. for C15H28N2O2Na: 291.2048, 
found: 291.2050. 
 
General procedure for the synthesis of (S)-tert-butyl 2-((R)-2-
acrylamidopent-4-enyl)piperidine-1-carboxylate (5a), (R)-tert-
butyl 2-((R)-2-acrylamidopent-4-enyl)piperidine-1-
carboxylate (5b), (R)-tert-butyl 2-((S)-2-acrylamidopent-4-
enyl)piperidine-1-carboxylate (5c), (S)-tert-butyl 2-((S)-2-
acrylamidopent-4-enyl)piperidine-1-carboxylate (5d). 
TEA (0.311 mL, 2.24mmol) w as added to a solution of 4 (0.272 g, 
1.02 mmol) in anhydrous CH2Cl2 (3.2 mL) cooled at 0°C. After 10 
minutes, acryloyl chloride (0.124 mL, 1.52 mmol) w as slow ly 
added dropw ise. The reaction mixture w as stirred for 2 h at room 
temperature, then NH4Cl w as added and the reaction mixture was 
extracted w ith CH2Cl2. The collected organic phases w ere 
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w ashed tw ice w ith brine, dried over Na2SO4, f iltered and 
concentrated under vacuum. The crude w as purif ied by column 
chromatography on silica gel (CH2Cl2/MeOH, 9:1) to give 5 as a 
light yellow  oil. 
 
(S)-tert-butyl 2-((R)-2-acrylamidopent-4-enyl)piperidine-1-
carboxylate (5a). Yield: 63%, 1H NMR (400 MHz, CDCl3) δ 6.30 
(dd, J = 17.0, 1.2 Hz, 1H), 6.13 (dd, J = 17.0, 10.3 Hz, 1H), 5.86 
– 5.69 (m, 1H), 5.64 (dd, J = 10.3, 1.2 Hz, 1H), 5.20 – 4.96 (m, 
2H), 4.28 (m, 1H), 4.07 (m, 1H), 3.96 (m, 1H), 2.85 (t, 1H), 2.38 – 
2.16 (m, 2H), 1.83 – 1.64 (m, 2H), 1.63 – 1.63 (m, 5H), 1.47 (s, 
9H), 1.38-1.32 (m, 1H) ppm. 13C NMR (100 MHz, CDCl3) δ 165.96, 
155.84, 135.23, 131.93, 126.65, 118.40, 80.26, 47.80, 47.13, 
40.32, 39.55, 34.21, 29.18 (3CH3), 28.81, 26.09, 19.63 ppm. [α]D
20  
= -26 (c = 0.88, CHCl3). ESIMS m/z [M + Na]
+ calcd. for 
C18H30N2O3Na: 345.2154, found: 345.2153. 
 
(R)-tert-butyl 2-((S)-2-acrylamidopent-4-enyl)piperidine-1-
carboxylate (5c). Yield: 61%, [α]D
20 = +28 (c = 0.91, CHCl3 ) , 
ESIMS m/z [M + Na]+calcd. for C18H30N2O3Na: 345.2154, found: 
345.2156. 
 
(R)-tert-butyl 2-((R)-2-acrylamidopent-4-enyl)piperidine-1-
carboxylate (5b). Yield: 66%, 1H NMR (400 MHz, CDCl3) δ 6.24 
(dd, J = 17.0, 1.6 Hz, 1H), 6.06 (dd, J = 17.0, 10.2 Hz, 1H), 5.85 
– 5.70 (ddt, J = 17.2, 10.2, 7.1 Hz, 1H), 5.58 (dd, J = 10.2, 1.5 Hz, 
1H), 5.15 – 5.01 (m, 2H), 4.35 (m, 1H), 4.01 – 3.85 (m, 2H), 2.73 
(td, J = 13.2, 2.2 Hz, 1H), 2.42 (m, 1H), 2.36 (m, 1H), 1.87 (ddd, 
J = 14.0, 8.0, 5.5 Hz, 1H),1.71 (dt, J = 14.0, 5.8 Hz, 1H), 1.67 – 
1.50 (m, 5H), 1.45 (s, 9H), 1.43 – 1.32 (m, 1H) ppm. 13C NMR 
(100 MHz, CDCl3) δ 165.02, 155.07, 134.71, 131.40, 125.80, 
117.70, 79.67, 47.32 (2 CH), 39.27, 37.83, 33.45, 29.62, 28.49 
(3CH3), 25.51, 19.06 ppm. [α]D
20 = -23 (c = 1.17, CHCl3). ESIMS 
m/z [M + Na]+ calcd. for C18H30N2O3Na: 345.2154, found: 
345.2155. 
 
(S)-tert-butyl 2-((S)-2-acrylamidopent-4-enyl)piperidine-1-
carboxylate (5d). Yield: 64%, [α]D
20 = +20 (c = 0.97, CHCl3 ) . 
ESIMS m/z [M + Na]+ calcd. for C18H30N2O3 Na: 345.2154, found: 
345.2157. 
 
General procedure for the synthesis of (S)-tert-butyl 2-(((R)-
6-oxo-1,2,3,6-tetrahydropyridin-2-yl)methyl)piperidine-1-
carboxylate (6a), (R)-tert-butyl 2-(((R)-6-oxo-1,2,3,6-
tetrahydropyridin-2-yl)methyl)piperidine-1-carboxylate (6b), 
(R)-tert-butyl 2-(((S)-6-oxo-1,2,3,6-tetrahydropyridin-2-
yl)methyl)piperidine-1-carboxylate (6c), (S)-tert-butyl 2-(((S)-
6-oxo-1,2,3,6-tetrahydropyridin-2-yl)methyl)piperidine-1-
carboxylate (6d). 
A solution of Umicore M73 SIMes catalyst (4.2 mg, 0.0057 mmol)  
in anhydrous CH2Cl2 (8 mL) w as added dropw ise to a solution of 
5 (0.183 g, 0.57mmol) in anhydrous CH2Cl2 (24 mL). The reaction 
mixture w as stirred for 2 h at 50°C, then the solvent w as removed 
under vacuum. The residue w as purif ied by column 
chromatography on silica gel (CH2Cl2/MeOH, 95:5) to give 6 as a 
w hite amorphous solid. 
 
(S)-tert-butyl 2-(((R)-6-oxo-1,2,3,6-tetrahydropyridin-2-
yl)methyl)piperidine-1-carboxylate (6a). Yield: 73%, 1H NMR 
(400 MHz, CDCl3) δ 6.66 – 6.52 (m, 1H), 5.91 (d, J = 9.9 Hz, 1H), 
4.33 (m, 1H), 3.98 (m, 1H), 3.59 – 3.47 (m, 1H), 2.76 (t, J = 12.9 
Hz,1H), 2.56 (dt, J = 17.6, 5.0 Hz, 1H), 2.27 – 2.08 (m, 1H), 2.08 
– 1.93 (m, 2H), 1.76 – 1.51 (m, 5H), 1.47 (s, 9H), 1.44-1.36 (m, 
1H) ppm. 13C NMR (100 MHz, CDCl3) δ 167.08, 155.61, 141.10, 
125.31, 80.61, 49.79, 47.99, 39.81, 36.85, 30.57, 29.91, 29.11 
(3CH3), 26.06, 19.68 ppm. [α]D
20 = +13 (c = 0.91, CHCl3), ESIMS 
m/z [M + Na]+ calcd. for C16H26N2O3Na: 317.1841, found: 
317.1845. 
HPLC analysis: Chiralcel AD-RH RP column, 1 mL/min, 
CH3CN:H2O = 35:65, 96 bar, λ: 254 nm, tR: 7.70 min, ee%: 92%. 
 
(R)-tert-butyl 2-(((S)-6-oxo-1,2,3,6-tetrahydropyridin-2-
yl)methyl)piperidine-1-carboxylate (6c). Yield:77%, [α]D
20 = -13 
(c = 1.2, CHCl3). ESIMS m/z [M + Na]
+ calcd. for C16H26N2O3 Na: 
317.1841, found: 317.1842. HPLC analysis: Chiralcel AD-RH RP 
column, 1 mL/min, CH3CN:H2O = 35:65, 96 bar, λ: 254 nm, tR: 
10.17 min, ee%: 92%. 
 
(R)-tert-butyl 2-(((R)-6-oxo-1,2,3,6-tetrahydropyridin-2-
yl)methyl)piperidine-1-carboxylate (6b). Yield: 80%, 1H NMR 
(400 MHz, CDCl3) δ 6.62 – 6.44 (m, 1H), 5.89 (dd, J = 9.9, 1.4 Hz, 
1H), 4.41 (m, 1H), 3.99 (m, 1H), 3.36 (m, 1H), 2.65 (t, J = 12.5 Hz, 
1H), 2.59 - 2.48 (m, 1H), 2.14 (dt, J = 17.8, 4.7 Hz, 1H), 1.90 (m, 
1H), 1.81 – 1.66 (m, 1H), 1.59 (m, 4H), 1.54 – 1.39 (m, 11H).1 3C 
NMR (101 MHz, CDCl3) δ 165.69, 139.68, 124.66, 47.34 (2CH) , 
38.70, 35.74, 30.04, 29.45, 28.56 (3CH3), 25.61, 19.28 ppm 
(detected signals). [α]D
20 = -66 (c = 0.85, CHCl3), ESIMS m/z [M 
+ Na]+ calcd. for C16H26N2O3Na: 317.1841, found: 317.1840, 
HPLC analysis: Chiralcel AD-RH RP column, 1 mL/min, 
CH3CN:H2O = 35:65, 96 bar, λ: 254 nm, tR: 8.71 min, ee%: 83%. 
 
(S)-tert-butyl 2-(((S)-6-oxo-1,2,3,6-tetrahydropyridin-2-
yl)methyl)piperidine-1-carboxylate (6d). Yield: 78%, [α]D
20 = 
+60 (c= 0.94, CHCl3). ESIMS m/z [M + Na]
+ calcd. for C16H26N2O3  
Na: 317.1841, found: 317.1843. HPLC analysis: Chiralcel AD-RH 
RP column, 1 mL/min, CH3CN:H2O = 35:65, 96 bar, λ: 254 nm, tR: 
11.15 min, ee%: 82%. 
 
General procedure for the synthesis of (R)-2-(((R)-6-oxo-
1,2,3,6-tetrahydropyridin-2-yl)methyl)piperidinium 2,2,2-
trifluoroacetate (7b) and (S)-2-(((S)-6-oxo-1,2,3,6-
tetrahydropyridin-2-yl)methyl)piperidinium 2,2,2-
trifluoroacetate (7d). 
TFA (65 μL, 0.85 mmol) w as added to a solution of 6 (0.031 g, 
0.11mmol) in anhydrous CH2Cl2 (17 mL), cooled at 0°C. The 
reaction mixture w as stirred at room temperature for 18 h, then 
the solvent w as removed under vacuum, affording 7 as CF3COOH 
salt (w hite amorphous solid). 
 
(R)-6-((R)-piperidin-2-ylmethyl)-5,6-dihydropyridin-2(1H)-one 
(7b). CF3COOH salt. Yield: 66%,
1H NMR (400 MHz, CDCl3) δ 
9.06 – 8.56 (m, 2H), 7.86 (bs, 1H), 6.67 (m, 1H), 5.90 (d, J = 9.3 
Hz, 1H), 3.89 (m, 1H), 3.50 – 3.36 (m, 1H), 3.36 – 3.21 (m, 1H), 
2.91 (m, 1H), 2.65 – 2.47 (m, 1H), 2.30 – 2.17 (m, 1H), 2.05 – 
1.79 (m, 5H), 1.79 – 1.67 (m, 1H), 1.67 – 1.58 (m, 1H), 1.54 (m, 
1H).13C NMR (100 MHz, CDCl3) δ 168.69, 167.18, 161.33 (q), 
142.50, 123.13, 53.36, 46.06, 45,03, 38.53, 29.51, 28.87, 22.30, 
22.09.[α]D
20-25 (c=0.62, MeOH), ESIMS m/z calcd. for 
[C11H19N2O]
+: 195.1497, found: 195.1501. 
 
(S)-6-((S)-piperidin-2-ylmethyl)-5,6-dihydropyridin-2(1H)-one 
(7d). CF3COOH salt. Yield: 70%,[α]D
20 +20 (c=0.70, MeOH) , 
ESIMS m/z calcd. for [C11H19N2O]
+: 195.1497, found: 195.1499. 
 
General procedure for the synthesis of (2S,6R,11aS)-
decahydro-4H-2,6-methanopyrido[1,2-a][1,5]diazocin-4-one 
(8a) and (2R,6S,11aR)-decahydro-4H-2,6-methanopyrido[1,2-
a][1,5]diazocin-4-one (8c). 
TFA (120 μL, 1.25 mmol) w as added to a solution of 6 (0.023 g, 
0.08 mmol) in anhydrous CH2Cl2 (13 mL), cooled at 0°C. The 
reaction mixture w as stirred at room temperature for 18 h, then 
the solvent w as removed under vacuum. The residue w as purif ied 
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by column chromatography on silica gel (CH2Cl2/MeOH, 95:5 to 
85:15), to give the 8 as CF3COOH salt (w hite amorphous solid). 
 
(2S,6R,11aS)-decahydro-4H-2,6-methanopyrido[1,2-
a][1,5]diazocin-4-one (8a). CF3COOH salt. Yield: qt%. 
1H NMR 
(400 MHz, CD3OD) δ 3.65 (bs, 1H), 3.33 – 3.19 (m, 1H), 2.71 (m, 
3H), 2.54 (m, 1H), 2.36 (dd, J = 19.1, 5.8 Hz, 1H), 2.18 – 1.90 (m, 
2H), 1.87 – 1.50 (m, 5H), 1.48 – 1.30 (m, 3H).13C NMR (100 MHz , 
CD3OD) δ 174.41, 163.05 (q), 55.00, 53.30, 53.02, 46.56, 39.88, 
33.16, 31.51, 30.29, 26.21, 24.98 (detected signals). [α]D
20 =+30 
(c= 1.18, MeOH), ESIMS m/z calcd. for [C11H19N2O]
+: 195.1497, 
found: 195.1498. 
 
(2R,6S,11aR)-decahydro-4H-2,6-methanopyrido[1,2-
a][1,5]diazocin-4-one (8c). CF3COOH salt. Yield: qt%. [α]D
20 =-
29 (c= 1.20, MeOH), ESIMS m/z calcd. for [C11H19N2O]
+:  
195.1497, found: 195.1499. 
 
General procedure for the synthesis of (11aS,12aR)-
6,8,9,10,11,11a,12,12a-octahydrodipyrido[1,2-c:1',2'-
f]pyrimidin-4(1H)-one (9a), (11aR,12aR)-
6,8,9,10,11,11a,12,12a-octahydrodipyrido[1,2-c:1',2'-
f]pyrimidin-4(1H)-one (9b), (11aR,12aS)-
6,8,9,10,11,11a,12,12a-octahydrodipyrido[1,2-c:1',2'-
f]pyrimidin-4(1H)-one (9c), (11aS,12aS)-
6,8,9,10,11,11a,12,12a-octahydrodipyrido[1,2-c:1',2'-
f]pyrimidin-4(1H)-one (9d). 
A 37% aqueous solution of formaldehyde (20μL, 0.28 mmol) and 
formic acid (11 μL, 0.28 mmol) w ere added to a solution of 6 
(0.050 g, 0.16 mmol) in CH3CN (0.9 mL). The reaction mixture 
w as stirred for 2 h at 90°C, then other 20μL of formaldehyde 
solution and 11 μL of formic acid w ere added. The reaction 
mixture w as stirred at 90°C for 12 h. The solvent w as removed 
under vacuum and the residue w as dissolved in CH2Cl2 and 
w ashed w ith a saturated aqueous NaHCO3. The aqueous layer 
w as extracted w ith CH2Cl2 and the combined organic phases w ere 
dried over Na2SO4, f iltered and concentrated under vacuum. The 
crude product w as purif ied by column chromatography on silica 
gel (CH2Cl2/MeOH, 98:2 to 95:5), to give 9 as a yellow  amorphous  
solid. 
 
(11aS,12aR)-6,8,9,10,11,11a,12,12a-octahydrodipyrido[1,2-
c:1',2'-f]pyrimidin-4(1H)-one (9a). Yield: 68%, 1H NMR (400 
MHz, CDCl3) δ 6.50 (ddd, J = 10.0, 5.3, 3.0 Hz, 1H), 5.89 (dd, J = 
10.0, 1.6 Hz, 1H), 5.18 (d, J = 11.0 Hz, 1H), 3.65 – 3.44 (m, 1H), 
3.03 (d, J = 11.0 Hz, 1H), 2.94 (d, J = 10.6 Hz, 1H), 2.50 (dt, J = 
18.0, 5.8 Hz, 1H), 2.26 (ddt, J = 16.4, 10.5, 2.7 Hz, 1H), 2.18 – 
1.98 (m, 2H), 1.81 – 1.51 (m, 6H), 1.42-1.29 (m, 2H).13C NMR 
(100 MHz, CDCl3) δ 164.56, 138.70, 124.33, 65.23, 60.49, 53.17, 
51.64, 39.14, 31.69, 29,65, 24.87, 23.55.[α]D
20 =+46 (c= 0.60, 
CHCl3), ESIMS m/z [M + Na]
+calcd. for C12H18N2ONa: 229.1317, 
found: 229.1319. 
 
 
(11aR,12aS)-6,8,9,10,11,11a,12,12a-octahydrodipyrido[1,2-
c:1',2'-f]pyrimidin-4(1H)-one (9c). Yield: 65% [α]D
20 =-47 (c= 
0.55, CHCl3), ESIMS m/z [M + Na]
+ calcd. for C12H18N2ONa: 
229.1317, found: 229.1318. 
 
(11aR,12aR)-6,8,9,10,11,11a,12,12a-octahydrodipyrido[1,2-
c:1',2'-f]pyrimidin-4(1H)-one (9b). Yield: 80%. 1H NMR (400 
MHz, CDCl3) δ 6.54 – 6.43 (m, 1H), 5.90 (dd, J = 9.8, 2.5 Hz, 1H), 
4.63 (d, J = 10.5 Hz, 1H), 3.92 (m, 1H), 3.84 (d, J = 10.5 Hz, 1H), 
2.90 (d, J = 11.6 Hz, 1H), 2.42 (m, 1H), 2.37 – 2.25 (m, 2H), 2.18 
– 2.04 (m, 1H), 1.92 (ddd, J = 13.6, 11.7, 8.7 Hz, 1H), 1.78 (d, J 
= 12.9 Hz, 1H), 1.63 – 1.53 (m, 3H), 1.52 – 1.46 (m, 2H), 1.37-
1.29 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 164.50, 138.62, 
125.84, 62.63, 58.43, 54.22, 48.10, 37.11, 32.18, 31.26, 
25.21(2CH2). [α]D
20 =+16 (c= 0.62, CHCl3), ESIMS m/z [M + Na]
+  
calcd. for C12H18N2ONa: 229.1317, found: 229.1320. 
 
(11aS,12aS)-6,8,9,10,11,11a,12,12a-octahydrodipyrido[1,2-
c:1',2'-f]pyrimidin-4(1H)-one (9d). Yield: 77%, [α]D
20= -13 (c= 
0.70, CHCl3), ESIMS m/z [M + Na]
+ calcd. for C12H18N2ONa: 
229.1317, found: 229.1321. 
 
1-piperidin-2-yl)pent-4-en-2-ol (11). 
TFA (2.2 mL. 28.0 mmol) w as added to a solution of 3-anti (0.500 
g, 1.84 mmol, racemic) in CH2Cl2 (20 mL), cooled at 0°C. The 
reaction mixture w as stirred at room temperature for 18 h, then 
the solvent w as removed under vacuum. The product (light yellow  
w ax) didn’t require further purif ication.  
 
CF3COOH salt. Yield: 90%, 
1H NMR (400 MHz, CDCl3) δ 8.36 (bs, 
1H), 7.83 (bs, 1H), 5.87 – 5.57 (m, 1H), 5.27 – 5.00 (m, 2H), 4.11 
– 3.83 (m, 1H), 3.46 (m, 1H), 3.23 (m, 1H), 3.03 – 2.80 (m, 1H), 
2.25 (m, 2H), 2.13 – 1.62 (m, 7H), 1.62 – 1.43 (m, 1H). 13CNMR 
(100 MHz, CDCl3) δ 161.34, 133.07, 119.19, 71.44, 58.56, 45.05, 
42.62, 38.44, 29.68, 22.20 (2CH2) (detected signals). ESIMS m/z  
calcd. for [C10H20NO]
+: 170.1545, found: 170.1544. 
 
Computational Studies 
Compounds syn- and anti-structures (see Figure 2) w ere 
optimized at the semiempirical level w ith the PM6 method.Errore . 
Il segnalibro non è definito. Transition states w ere built  
assuming a late transition state, similar in energy to the f inal 
products, according to Hammond’s postulate. TS and minima 
w ere identif ied throughfrequency calculation. 
Intrinsic reaction coordinate pathw ay connecting the reactants to 
the transition state w as also computed at the semiempirical PM6 
level. All calculations w ere performed w ith the Gaussian 2016 
package Gaussian 16, Revision B.01.[32] 
 
Keywords: piperidine derivatives • diversity-oriented synthesis • 
2-Piperidine Ethanol • stereodivergent synthesis • piperidine 
alkaloids. 
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